Screener
Crinetics Pharmaceuticals CRNX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued compensation and related expenses | 25,792 | 35,578 |
| Deferred revenue | 1,271 | 1,235 |
| Operating lease liabilities | 6,536 | 6,489 |
| Total current liabilities | 71,086 | 85,072 |
| Operating lease liabilities, non-current | 41,319 | 42,052 |
| Deferred revenue, non-current | 3,346 | 3,810 |
| Other liabilities | 4,926 | 3,240 |
| TOTAL LIABILITIES | 120,677 | 134,174 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's total current liabilities?
- Crinetics Pharmaceuticals (CRNX) reported total current liabilities of $71.09M in Q1 2026.
- How has Crinetics Pharmaceuticals's total current liabilities changed year-over-year?
- Crinetics Pharmaceuticals's total current liabilities increased by 24.0% year-over-year, from $57.31M to $71.09M.
- What is the long-term trend for Crinetics Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's total current liabilities has grown at a 52.0% compound annual growth rate (CAGR), from $10.49M to $85.07M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Crinetics Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude